This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generex Reports On Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting

WORCESTER, Mass. and TORONTO, June 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) reported today that the inaugural meeting of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., for the company's AE37 breast cancer vaccine took place in Dallas, TX on May 19, 2012.

(Logo: )

The following distinguished scientists, scholars, and physicians joined representatives of Generex and Antigen Express at the SAB meeting:  Dr. Kathy D. Miller, MD ( Indiana University School of Medicine Melvin and Bren Simon Cancer Center); Dr. Ian Krop, MD, PhD (Dana-Farber Cancer Institute, Harvard Medical School); Dr. James J. Mule, MD (Moffitt Cancer Centre); Dr. Keith L. Knutson, PhD (Mayo Clinic); Dr. Nuhad Ibrahim, MD (MD Anderson Cancer Center); Dr. Hope S. Rugo, MD ( University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center); and, Dr. Samuel Jacobs, MD (National Surgical Adjuvant Breast and Bowel Project (NSABP).

Dr. Eric von Hofe, PhD, President of Antigen Express, reported:  "We had a successful and productive inaugural SAB meeting.  We are gratified that these key opinion leaders have recognized the potential of our AE37 breast cancer vaccine and joined with us to maximize the potential for clinical and regulatory success.  We have received invaluable input regarding our pending transition into a Phase III clinical trial of the vaccine."

Generex is also proud to announce that the following physicians have joined the SAB:

Dr. Samuel Jacobs, MD Director, Medical Affairs National Surgical Adjuvant Breast and Bowel Project (NSABP)

Dr. Samuel Jacobs, MD is an emeritus Clinical Professor in the Department of Medicine, University of Pittsburgh School of Medicine, and the Director of Medical Affairs for the National Surgical Adjuvant Breast and Bowel Project (NSABP).  Dr. Jacobs has a long and distinguished career as a clinical researcher in the fields of breast oncology and lymphoma.  His recent focus has been in area of developmental therapeutics. 

For the last four years, Dr. Jacobs has been intimately involved with the research efforts of the NSABP Foundation, Inc., which has more than 700 research sites in North America and an international network of oncology and research professionals.  The NSABP pioneered breast cancer studies that led to the establishment of lumpectomy plus radiation over mastectomy as the standard surgical treatment for breast cancer and was also the first group to demonstrate that adjuvant therapy (treatment in addition to surgery) could alter the natural history of breast cancer, increase survival rates, and prevent recurrence using chemotherapy as well as hormonal therapies.

In addition to his work in oncology treatment protocols, Dr. Jacobs has also conducted considerable research on the logistics and management of the clinical trial process in oncology.  He has led the efforts at the University of Pittsburgh Clinical Research Service to provide study development and implementation assistance, IRB processing, patient recruitment, study coordination, and specimen and data collection for all investigators conducting cancer-related studies at all UPMC Cancer Centers.

Dr. Jacobs received his MD from the University of Rochester, and has spent his career making the University of Pittsburgh Medical Center a leading institution in the field of oncology and cancer management.

With respect to his participation on the SAB, Dr. Jacobs states:  "Based on the exciting preliminary Phase II data on the AE37 vaccine in adjuvant treatment of breast cancer, it is possible that this vaccine will have a major impact on the future treatment of a subset of early breast cancer patients.  It seems clearly worthwhile to carefully determine its utility in a large well-conducted trial."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs